Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) CFO Sells 2,850 Shares of Company Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of the company’s stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $72.87, for a total transaction of $207,679.50. Following the sale, the chief financial officer directly owned 166,143 shares of the company’s stock, valued at approximately $12,106,840.41. This represents a 1.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP traded down $1.16 during mid-day trading on Friday, hitting $72.00. 286,882 shares of the company’s stock traded hands, compared to its average volume of 378,435. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of 15.52, a price-to-earnings-growth ratio of 2.31 and a beta of 0.50. The firm has a 50 day moving average of $73.06 and a two-hundred day moving average of $77.74. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a 12 month low of $69.58 and a 12 month high of $95.57.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17. The company had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business’s revenue was up 25.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on ANIP shares. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They set an “outperform” rating and a $104.00 target price for the company. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Guggenheim reduced their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Finally, Oppenheimer initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $99.60.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANIP. Oregon Public Employees Retirement Fund lifted its position in ANI Pharmaceuticals by 9.7% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 4,539 shares of the specialty pharmaceutical company’s stock valued at $330,000 after purchasing an additional 400 shares during the period. Bridge City Capital LLC boosted its stake in shares of ANI Pharmaceuticals by 56.7% in the 3rd quarter. Bridge City Capital LLC now owns 52,705 shares of the specialty pharmaceutical company’s stock valued at $3,829,000 after purchasing an additional 19,080 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of ANI Pharmaceuticals during the 3rd quarter worth approximately $85,000. Profund Advisors LLC grew its position in shares of ANI Pharmaceuticals by 443.7% during the 3rd quarter. Profund Advisors LLC now owns 22,656 shares of the specialty pharmaceutical company’s stock worth $1,646,000 after buying an additional 18,489 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al grew its position in shares of ANI Pharmaceuticals by 7.4% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 18,800 shares of the specialty pharmaceutical company’s stock worth $1,366,000 after buying an additional 1,300 shares during the period. 76.05% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.